Title: Dasatinib Achieves Higher Response Rate Than Imatinib in CML
Abstract:A study comparing dasatinib to imatinib in patients with chronic myeloid leukemia found that the second-generation TKI dasatinib yielded better remission and molecular response rates than imatinib, bu...A study comparing dasatinib to imatinib in patients with chronic myeloid leukemia found that the second-generation TKI dasatinib yielded better remission and molecular response rates than imatinib, but these did not result in better survival outcomes.Read More
Publication Year: 2012
Publication Date: 2012-09-06
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot